Abivax holder Sofinnova trims stake to 7.7% voting
Abivax S.A. shareholder Sofinnova Crossover I SLP and affiliated reporting persons update their ownership after selling American depositary shares in the market.
Rhea-AI Filing Summary
Abivax S.A. shareholder Sofinnova Crossover I SLP and affiliated reporting persons update their ownership after selling American depositary shares in the market. On January 12 and 13, 2026, Sofinnova Crossover I SLP sold multiple blocks of Abivax ADSs in open‑market transactions at weighted average prices ranging from $118.27 to $141.26 per ADS, plus a separate trade of 100 ADS at $142.00 per ADS.
As of January 14, 2026, Sofinnova Crossover I SLP holds 3,334,739 Ordinary Shares, representing about 4.3% of Abivax’s 78,398,795 Ordinary Shares outstanding as of November 30, 2025. These shares carry 6,399,478 voting rights, or 7.7% of the 82,688,932 voting rights outstanding. The management company Sofinnova Partners SAS and investment committee members may be deemed to share voting and investment control, although the individuals disclaim beneficial ownership except for their pecuniary interests.
Positive
- None.
Negative
- None.
Insights
Large Abivax holder trims its position but remains a significant voting shareholder.
Sofinnova Crossover I SLP reports open‑market sales of Abivax American depositary shares on January 12, 2026 and January 13, 2026. The trades occurred in multiple blocks, with weighted average prices between $118.27 and $141.26 per ADS, plus a 100‑ADS sale at $142.00. This reflects active portfolio management by a financial sponsor rather than a change disclosed in Abivax’s operations.
After these transactions, Sofinnova Crossover I SLP directly holds 3,334,739 Ordinary Shares, equal to about 4.3% of the 78,398,795 Ordinary Shares outstanding as of November 30, 2025. These shares correspond to 6,399,478 voting rights, or 7.7% of the 82,688,932 voting rights outstanding, keeping Sofinnova a notable voting bloc. The filing states the shares were acquired for investment purposes and that the reporting persons may buy or sell further securities as permitted by law.
The management company Sofinnova Partners SAS and committee members Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson, and Jacques Theurillat may be deemed to share voting and investment control over Sofinnova Crossover I SLP’s holdings. The individuals disclaim beneficial ownership beyond their pecuniary interests. Future ownership levels will depend on any additional transactions the group may choose to undertake, which would be reflected in subsequent beneficial ownership reports.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake does Sofinnova currently report in Abivax (ABVX)?
What transactions triggered this Schedule 13D/A amendment for Abivax (ABVX)?
Who are the reporting persons in this Abivax (ABVX) Schedule 13D/A filing?
How much voting influence does Sofinnova have in Abivax (ABVX)?
AI-generated analysis. How Rhea-AI works. Not financial advice.